Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients
To the Editor:
Lower respiratory tract infections (LRTIs) are a leading reason for hospitalization and mortality in hematopoietic cellular transplant (HCT) recipients (1) . Despite this, the etiologic pathogens often remain unidentified because of reduced yields of traditional diagnostics in the setting of prophylactic antimicrobials, reduced antibody titers, and infections from uncommon opportunistic microorganisms. Metagenomic next-generation sequencing (mNGS) may offer enhanced diagnostic capabilities by providing culture-independent, comprehensive measurement of the microbial composition of clinical samples (2, 3) . By capturing both microbial and human RNA, mNGS also permits simultaneous transcriptional profiling of the host immunologic response and can deliver rapid (,48 h) and actionable microbiologic data for precise infectious disease diagnosis (2) .
As a result of the clear need for enhanced LRTI diagnostics in HCT recipients, we sequentially enrolled 22 adult HCT recipients hospitalized for acute respiratory illnesses who underwent bronchoscopy and BAL between January 25, 2012, and May 20, 2013, under University of Michigan protocol HUM00043287. Standard-of-care BAL microbiologic testing was uniformly performed on all patients and included semiquantitative cultures for bacteria, mycobacteria, fungi, and cytomegalovirus; Aspergillus galactomannan assay; silver stain for Pneumocystis jirovecii; multiplex polymerase chain reaction influenza A/B, respiratory syncytial virus and human metapneumovirus; and human herpesvirus-6 polymerase chain reaction, as detailed in the Methods in the online supplement (4) . Additional diagnostics were performed on blood and nasopharyngeal samples at the discretion of the treating physicians, as described in Table 1 and detailed in the online supplement (4) .
RNA and DNA sequencing libraries were constructed from 250 ml BAL from each patient and underwent paired-end Illumina sequencing according to established methods (4) . Pathogen detection leveraged a custom bioinformatics pipeline that discriminates pathogens from background microbial contaminants in clinical samples (2, 3) . A ranking score consisting of the nucleotide reads aligned per million reads sequenced (rpM) multiplied by the sum of the nt and nr Z-scores for each genus relative to no-template controls was used [score = rpM nt 3 (Z nt 1 Z nr )] (4).
Microbes identified were classified as confirmed pathogens if 1) both clinical testing and mNGS identified the microbe, 2) there existed literature evidence of pathogenicity in the lungs, and 3) the score was as least twofold greater than that of any other microbe of the same type (virus, bacteria, or fungus) identified in the patient. Microbes were considered new potential pathogens if mNGS alone identified the microbe and criteria 2 and 3 described here were met; all other microbes were considered unlikely or uncertain pathogens. Findings were independently confirmed by viral PCR or bacterial 16S rRNA gene sequencing, as described (4) .
Standard-of-care clinical diagnostics identified microbes in seven patients (32%), six of which were considered pathogens by treating physicians, and all of which were detected by mNGS (Table 1 ). In addition, mNGS identified well-recognized respiratory pathogens in six patients with otherwise negative testing, including human coronavirus 229E and human rhinovirus A (HRV-A); the former, despite being a leading cause of communityacquired pneumonia (5), is still not included as a target on many clinical respiratory viral PCR panels. With respect to potential bacterial pathogens, mNGS identified Streptococcus mitis in patient 13, an oropharyngeal microbe known to cause bacteremia and acute respiratory distress in HCT recipients (6) , and Corynebacterium proprinquum, one of the few virulent Corynebacterium species associated with LRTI (7). mNGS identified a diversity of DNA viruses including human herpesvirus-6, cytomegalovirus, herpes simplex virus, Epstein-Barr virus, human papilloma virus, and torque teno viruses; however, only five of these also had well-defined evidence of active replication marked by detectable RNA transcripts (Table 1) . mNGS identified microbes of uncertain pathogenicity in nine patients (Table 1) who had coexisting clinical diagnoses of graft-versus-host disease (patients 11, 22, 23, 24, 25, 31, 34, 35, and 37) or bacteremia/sepsis (patient 3), which could have contributed to respiratory symptoms resulting from noninfectious pulmonary inflammation. Because asymptomatic carriage of respiratory pathogens is well described (8) , establishing biomarkers of genuine infection is critical for determining the significance of a given microbiologic finding. Loss of diversity within respiratory tract microbial communities has been proposed as an ecological marker of infection (9), and we thus evaluated alpha diversity of microbes identified by RNA sequencing and found that subjects with confirmed pathogens had a significantly lower Simpson's diversity index than patients with microbes of unlikely or uncertain pathogenicity (median, 0. (4, 10) . We observed that two of the three HRV-A-positive subjects demonstrated the lowest expression of this immune response metric, whereas the remaining subject, who was coinfected with HRV-A and Stenotrophomonas maltophilia, had one of the highest values, consistent with prior reports demonstrating that HRV can induce a broad range of disease severity and that viral-bacterial coinfection can increase the severity of disease (8) .
Although these results are highly encouraging, this proofof-concept study suggests many routes for improvement. First, this study was limited by a relatively small sample size, only one case of culture-positive bacterial LRTI, no fungal infections, and no subjects with exclusively clinical diagnoses of noninfectious airway diseases. Second, our limited sequencing depth did not yield the human transcriptome coverage that would be desired for optimal differential gene expression analyses, although we were able to rigorously evaluate a composite metric of immunity genes. Future studies with larger cohorts are ongoing to validate the sensitivity and specificity of mNGS for LRTI diagnosis in this population and develop robust gene classifiers that can distinguish LRTI from noninfectious airway diseases in HCT recipients.
In summary, we leverage continued improvements in metagenomic sequencing to expand the capabilities of LRTI diagnostics in HCT recipients with acute respiratory illnesses. We demonstrate that compared with current microbial diagnostics, mNGS has a greater capacity for detecting microbes and an ability to couple pathogen detection with simultaneous profiling of the host response and the airway microbiome. n 
Peripheral and Alveolar Cell Transcriptional Programs Are Distinct in Acute Respiratory Distress Syndrome
Our understanding of transcriptomic responses in acute respiratory distress syndrome (ARDS) is derived, almost exclusively, from studies that have used samples procured from the peripheral circulation as opposed to the alveolar space (1) (2) (3) (4) We performed variance stabilization and quantile normalization of the raw microarray data, using the Bioconductor package lumi (7). Detailed microarray information has been deposited at Gene Expression Omnibus (https://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE89953). Principal component analysis was performed on the basis of whole-genome gene expression variability between paired AM and PBM samples (8) . Differential gene expression between the two cell populations was determined by a Bayesian implementation of the t test (http://cybert.microarray.ics.uci.edu) on log 2 -transformed probe intensities, using a sliding window size of 101 and a Bayesian confidence estimate value of 10. 
